NEW YORK (GenomeWeb) – Biomedical software startup BostonGene today announced that it has received a $50 million Series A investment from Japanese software giant NEC.
The Boston-based startup's platform helps clinicians find the proper combination of therapies for cancer patients, with a focus on immunotherapies and other targeted treatments. The patented technology combines molecular profiling, assessment of a patient's "immune fitness," and an artificial intelligence engine to comb through a curated database of cancer research and clinical knowledge for assessing oncological treatment options.
"NEC and BostonGene share a common vision of the immense potential of an AI-driven approach to cancer immunotherapy. Leveraging the strengths of both companies, we will be able to improve the survival rate and quality of life for cancer patients," Osamu Fujikawa, NEC senior vice president and head of the business innovation unit, said in a statement.
"An investment of this magnitude will support our vision, mission, and strategy, as well as the formation of synergies with the NEC health tech business to create meaningful new opportunities," added BostonGene President and CEO Andrew Feinberg.